ALTAltimmune, Inc.
$2.60-34% 1Y
$2.60
$2.5952 weeks$6.18
ALT in its own filings
ALT's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
496
Events found in the filings · across 1,458 filings · the record starts in 2005
- Hard flags
- 3
Hard flags
- Most recent filing
- Sep 29, 2026
Most recent filing · Form 8-K
- Record starts
- Jul 26, 2005
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountant3 occurrences
- 2017-06-27
- Late periodic reporthistorical
- 2017-08-10
- Delisting notice / listing-rule failure2 occurrences
- 2018-05-18
- Security removed from listing or deregistered3 occurrences · usually a matured note or preferred class, not the common shares
- 2017-05-05
- SEC comment-letter activity62 occurrences
- 2025-12-03
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso as the Company’s Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.Director or officer change · Form 8-K
- Aug 12, 2026Altimmune Announces Second Quarter 2026 Financial Results and Business Update.Earnings release · press release
- Jul 28, 2026As noted above, on July 28, 2026, the Company announced the positive topline results from the RECLAIM Phase 2 trial evaluating the 2.4 mg dose of pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe AUD. The trial met its primary endpoint with a highly …Regulation FD disclosure · Form 8-K
- Jun 16, 2026On June 16, 2026, Altimmune, Inc. (the “Company”) announced plans to relocate its corporate headquarters from Gaithersburg, Maryland to Morristown, New Jersey later this year.Other event · Form 8-K
- May 13, 2026Altimmune Announces First Quarter 2026 Financial Results and Business Update.Earnings release · press release
- Apr 24, 2026On April 22, 2026, Altimmune, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Barclays Capital Inc., as representatives of the several underwriters named therein (the “Underwriters”) pursuant to which the Company agreed to issue and sell (i) …Material agreement entered · Form 8-K
- Apr 16, 2026On April 16, 2026, Altimmune, Inc. (the “Company”) amended its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) by filing a Certificate of Amendment with the Secretary of State of Delaware.Charter/bylaw amendment or fiscal-year change · Form 8-K
- Mar 5, 2026Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates.Earnings release · press release
- Feb 3, 2026Altimmune, Inc. (the "Company") has established Thursday, April 16, 2026 as the date of the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") to align with the standard second quarter annual meeting calendar for companies operating on a 12/31 fiscal year-end.Other event · Form 8-K
- Jan 28, 2026On January 27, 2026, Altimmune, Inc. (the “Company”) entered into a Securities Purchase Agreement with a new fundamental institutional investor (the “Securities Purchase Agreement”) relating to the issuance of 12,397,920 shares of the Company’s common stock, par value of $0.0001 per share (the “Common Stock”) and …Material agreement entered · Form 8-K
- Dec 19, 2025On December 19, 2025, the Company announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis (“MASH”) at 48 weeks.Regulation FD disclosure · Form 8-K
- Dec 1, 2025On December 1, 2025, Altimmune, Inc. (the “Company”) announced that, effective January 1, 2026 (the “Transition Date”), Vipin K. Garg, Ph.D. will transition from his role as President and Chief Executive Officer.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…